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Abstract
Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian
Devils in the wild. The aim of this study was to determine the susceptibility of the DFTD to vincristine. Escalating dosage
rates of vincristine (0.05 to 0.136 mg/kg) were given to Tasmanian devils in the early stages of DFTD (n = 8). None of these
dosage rates impacted the outcome of the disease. A dosage rate of 0.105 mg/kg, a rate significantly higher than that given
in humans or domestic animals, was found to the highest dosage rate that could be administered safely. Signs of toxicity
included anorexia, vomiting, diarrhea and neutropenia. Pharmacokinetic studies showed that, as with other species, there
was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/
kg) and a relatively long elimination half life (11 h). Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than
in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil’s ability to tolerate
high dosage rates of vincristine. While providing base-line data for the use of vincristine in Tasmanian devils and possibly
other marsupials with vincristine susceptible cancers, these findings strongly suggest that vincristine will not be effective in
the treatment of DFTD.
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Introduction
Tasmanian devil facial tumor disease (DFTD) is an aggressive,
transmissible and uniformly fatal, malignancy of the Tasmanian
devil for which no treatment has been reported [1]. It is one of
only two known naturally occurring clonally transmissible cancers
(the other being transmissible venereal tumor of canids (CTVT)
[2]. DFTD is a monophyletic clonally transmissible tumor whose
dissemination appears possible by a down regulation of MHC
expression [3,4]. It is thought to be of Schwann cell origin [5]. It
was first described in 1996 and by 2006, it was estimated that 59%
of Tasmania was affected by the disease, accounting for population
declines of more than 80% in some areas [6]. Older animals have
declined as a proportion of the affected population, and the age at
breeding has compensatorily declined leading to a shift in life-
history of this species [1]. The Tasmanian devil was listed as
endangered by International Union for Conservation of Nature in
2009.
Clinically the disease appears as multiple, firm, raised soft-tissue
nodules and masses, which are often centrally ulcerated and
necrotic. As they progress, they ultimately become large space
occupying lesions. The anatomic distribution of DFTD lesions
suggests that transmission of transplantable tumor cells occurs
during ‘‘jaw-wrestling’’ a common interaction among Tasmanian
devils during mating [7]. In most cases, multiple lesions initially
arise on the face (especially oral areas) and neck, and it is
progressive growth of these lesions that leads to the death of most
of the affected animals. While the cause of death for most affected
Tasmanian devils is thought to be starvation, metastatic disease
occurs rapidly and widely. In affected captive animals the average
survival is approximately 3–6 months (our unpublished observa-
tion, 2010).
Current management strategies for this disease include isolation
of populations of Tasmanian devils by fencing or establishment of
isolated peninsulas, and capture and removal of affected
Tasmanian devils [8]. Additional ‘‘insurance’’ populations of
Tasmanian devils have been established in breeding colonies
around mainland Australia. With such reliance on captive
populations for survival of the species, investigation into treatment
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strategies would appear to be important; however none have been
reported to date.
Vincristine is effective against a wide range of cancer types due
to interference with the mitotic spindle apparatus, causing cell
death in mitosis [9]. It has been safely used in a wide range of
animal species including chickens, cats, monkeys, dogs, rats, mice
and guinea pigs [10]. Vincristine was administered weekly to 201
dogs with CTVT and resulted in a complete remission (CR: 100%
tumor reduction) in 197 dogs and a partial remission (PR: .50%
tumor reduction but less than CR) in one dog; only one dog
relapsed in a period of 12 months [11,12]. The most common
toxicities were mild, self-limiting vomiting or transient leukopenia,
seen in less than 15% of dogs; animals older than five years of age
were more likely to show gastrointestinal toxicities [13]. Similar
toxicities have been seen in cats, and at veterinary dosages used,
are considered by most pet owners to be compatible with normal
quality of life [14]. In addition to causing a cure in most dogs with
CTVT, responses in mesenchymal tumors (sarcomas) have been
reported in cats and dogs, implying there may be antitumor
efficacy in DFTD [15].
The treatment of wild animals of any species with chemother-
apy is probably not realistic, given the potential toxicities and need
for supportive care should they arise. On the other hand, the
Tasmanian devil is endangered, and it appears that the species
may not survive in the wild in sufficient numbers to maintain
genetic diversity. With that in mind, the establishment of satellite
colonies of Tasmanian devils has now been undertaken. Reliance
on relatively small captive populations for the survival of the
species means that effective treatment strategies would be very
important should DFTD arise in such animals. Additionally,
marsupials, in general, appear to be particularly prone to
neoplasia [16]. Many are species that are highly endangered and
many marsupials are kept in zoos and animal parks creating a
need for evidence-based treatment protocols for these species.
The initial objective of this study was to determine if a dosage
rate of vincristine could be established that would cause regression
of DFTD and produce minimal toxicity in the affected animals.
The second objective of this study was to determine the
pharmacokinetic parameters of vincristine in Tasmanian devils
with DFTD after a single intravenous dose.
Materials and Methods
Ethics Statement
All aspects of this project were reviewed and approved by the
Tasmanian Government Project Grants Ethics Committee, license
AEC Project 40/2007–08.
Animal Subjects
Wild Tasmanian devils with early stages of DFTD were
captured as part of the disease suppression trial and kept in
outdoor enclosures with free access to water, food and shelter at
the Department of Primary Industry and Water, Launceston,
Tasmania. Adult animals with lesions in the early stages of
development (defined as 3 or fewer primary lesions, with each
tumor measuring less than 4 cm in their widest dimension) were
selected for this treatment trial (n = 8) and to be used as untreated
controls (n = 8). Animals were acclimatized to captivity for a
minimum of one week before the onset of treatment.
Dosage Escalation Study
The first aim of this study was to determine the optimum dosage
rate and interval (minimally effective dose and maximally tolerated
dose) for vincristine in Tasmanian devils with DFTD. Vincristine
has not been extensively administered to marsupials to the
knowledge of the investigators. We expected that marsupials could
differ in their risk of toxicity from placental mammals, so rather
than rely on scaling from human, dog or cat dosages; a modified
Fibonacci dose escalation scheme was employed. Since body
surface area dosing has not been found to be reliable in placental
companion animals [17], dosage rates were calculated based on
body weight (mg/kg). Vincristine (Pfizer, West Ryde, New South
Wales) was administered by rapid (less than 1 minute) intravenous
bolus injection delivered to Tasmanian devils anaesthetized with
isoflurane (Pharmachem, Eagle Farm, Queensland). The dosage
was repeated weekly if Tasmanian devils did not show grade 3 or
higher toxicity (see below).
The starting vincristine dosage rate was based on dosage rates
used in clinical veterinary practice, and previously used safely in a
solitary Tasmanian devil by one of us (ASM). The plan was that at
each dosage rate, three Tasmanian devils would be treated and
evaluated for adverse events. If grade 3 or higher toxicity was not
seen then the dosage rate for the next cohort of three animals
would be increased according to Fibonacci’s Modified scheme
(Table 1). Vincristine was administered by bolus injection through
an over-the-needle intravenous catheter placed in either the lateral
saphenous, or distal cephalic vein. Catheters were first flushed with
5 mL 0.9% sodium chloride and were again flushed after injection
prior to removal using all necessary precautions to prevent human
exposure.
To evaluate toxicity to patients during this trial and to decide if
dose escalation was appropriate, previously published criteria were
used to evaluate adverse events, where an adverse event was
defined as any unfavorable and unintended clinical sign, or
abnormal clinicopathologic finding temporally associated with the
use of a treatment [18]. These adverse events were graded as to
their severity 1 through 5: Grade 1– Mild, Grade 2– Moderate,
Grade 3– Severe, Grade 4– Life-threatening or disabling, Grade
5– death (Table 2). General health was assessed by clinical
examination, daily assessment of activity, appetite and elimina-
tions, and by a complete blood count including platelet count,
serum biochemical profile and urinalysis prior to administering
each treatment and then every week when treatments were not
administered.
Supportive care during this trial was limited to providing anti-
nausea medications in the form of the parenteral NK-1 antagonist
antiemetic maropitant (CereniaTM Pfizer, West Ryde, New South
Wales) at the same dosage rate recommended for parenteral
treatment of dogs (1 mg/kg once daily), and the use of a
proprietary pet food formulated for palatability and high caloric
content (Prescription Diet a/d; Hills Pty Ltd., Topeka, Kansas). In
addition the non-steroidal anti-inflammatory meloxicam (Troy
Laboratories, Smithfield, New South Wales) was administered
parenterally if the lesions appeared inflamed or subjectively
painful, and the broad spectrum antibiotic enrofloxacin (Troy
Laboratories, Smithfield, New South Wales) was administered to
animals with infected lesions.
Tumor Response and Efficacy of Vincristine
In parallel with determining the optimal dosage rate and
interval, we evaluated the efficacy of vincristine in causing
remission of spontaneously occurring Tasmanian devil facial
tumors. The two greatest perpendicular dimensions of each tumor
were measured using calipers, and recorded. Response criteria
used in this trial were standard for veterinary oncology trials. A
complete response was defined as disappearance of all measurable
tumors; partial response was defined as decreased tumor diameters
of .50% but ,100%; stable disease was defined as a decrease in
Vincristine Trials in Tasmanian Devils
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tumor diameters of ,50% or an increase in size up to 25%;
progressive disease was categorized as an increase in tumor
diameters of.25%, or appearance of new tumor(s). Survival times
of animals receiving vincristine chemotherapy, and animals not
treated (n= 8) but maintained in identical captivity conditions
were compared using the Kaplan-Meier product limit method and
Cox regression analysis (SPSS Version 11.0).
The decision to euthanize each treated and untreated animal
was a subjective one whose criteria were applied equally to both
groups. It was based on assessment of deteriorating quality of life
(decreased appetite, reduced activity level and physical changes,
including weight loss) co-incident with advanced tumor growth; an
example is a fractured mandible that occurred due to tumor
invasion. That assessment was done by veterinary staff at the
holding facility and animal care attendants who had daily contact
with the animals.
Pharmacokinetic Analysis
Plasma samples to evaluate the pharmacokinetics of vincristine
were collected from Tasmanian devils following administration of
a single bolus dosage of vincristine. Samples were collected from 6
animals at a vincristine dosage of 0.05 and 0.091 mg/kg (n= 3 at
each dose).
All samples for pharmacokinetics analysis were collected
through the saphenous catheter that had not been used for
chemotherapy administration. Prior to each sample collection a
minimum of 0.5 ml of heparin block and blood was withdrawn
from the catheter and discarded. After the collection of each
sample the catheter was flushed again with heparinized saline
(3 mL). Blood samples for measurement of plasma vincristine
concentration were collected at 5, 15, 30, 60, 120, 240, 480 min
and 23 h after vincristine administration. Animals were anaesthe-
tized for 30 min after treatment; subsequent to that, blood samples
were collected through the same catheter with the animal
physically restrained. Venous catheters were removed after the
480 min sample collection and blood was drawn directly from the
lateral saphenous vein at the 23 h collection. Each blood sample
was transferred to heparinized tubes and centrifuged immediately
for 10 min. The plasma was harvested and stored at 280uC until
analyses.
Plasma samples were analyzed using a modification of
previously described and validated HPLC assays for vincristine
Table 1. Vincristine dosage rates, numbers of treatments and evidence of toxicity in Tasmanian Devils.
Vincristine Dosage Rate (mg/kg)
Toxicity (System/Grade)a,b
Treatment 1 2 3 4 5 6 7 8 9
No.
Animal
A 0.05c 0.05 0.05
B 0.05c 0.05 0.05 0.07 0.075 0.075 0.105
Ax1
D1




D 0.105 0.105 0.136 0.136 0.105 0.105 0.105
Ax1 Ax1 Ax1 Ax3 Ax3
D1
















aToxicity descriptions are for the week following the treatment.
bAbbreviations: Ax – Anorexia, Vm – vomiting, D – diarrhea, An – anemia, N – neutropenia. Numerical values related to toxicity grade.
cSamples were collected for the pharmacokinetic study following administration.
dAnimal was euthanized and hematology was not done.
doi:10.1371/journal.pone.0065133.t001
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[19,20]. Briefly, 250 ml of plasma was spiked with 20 ml of an
internal standard, vinblastine, (Velbe, Eli Lilly, Indianapolis,
Indiana) in an Eppendorf tube, to give a final concentration of
400 nmol/l. The sample was then diluted with 0.25 ml of 4%
phosphoric acid and mixed gently. The SPEC-DAU microdisc
SPE cartridges (Varian, Melbourne, Australia) were connected to
a Vac Elut and initially conditioned with 0.5 ml methanol,
followed by 0.5 ml of 0.1 M phosphate buffer (pH 3.0). Plasma
samples were then applied to each cartridge. The sample was
allowed to run through the column disc at a low flow rate of no
more than 1 ml/min. The cartridge was rinsed with 0.5 ml of
0.1 M phosphate buffer (pH 3.0), followed by 0.5 ml 20%
methanol and dried under vacuum. The analytes were eluted
with 1 ml of methanol-ammonia (95:5 v/v) at a low rate of no
more than 1 ml/min. The HPLC eluate was then dried under
vacuum in a SpeedVac vacuum evaporator (Savant Instruments,
Farmingdale, NY, USA) and the dried residue was re-dissolved in
50 ml of mobile phase. The mixture was then vortexed and
centrifuged to remove particulates. The supernatant was then
transferred to micro insert vials and 10 ml of reconstituted solution
was automatically injected into the HPLC system. Plasma
vincristine calibration curve of 10–400 nmol/l (9–370 ng/mL)
were also prepared similarly and obtained by concentration versus
the area ratio of vincristine to vinblastine (IS). The concentrations
of vincristine in the unknown samples were calculated from the
least-square linear regression equation of the calibration curve.
Chromatographic separation of vincristine and vinblastine (IS)
was accomplished using a Waters Symmetry C8 5 mm
(2.16150 mm) micro-bore reverse-phase column (Waters, Rydal-
mere, Australia) coupled with a 1 mm Opti-Guard C8 pre-column
(Optimize Technologies, Choice Analytical, Thornleigh, Austra-
lia). The mobile phase consisted of a mixture of 10 mM sodium
phosphate buffer (pH 6.5), acetonitrile and methanol (45:35:20, v/
v/v). The flow rate was maintained isocratically at 0.3 ml/min.
The eluent from the HPLC column was directed via a photo-
diode-array (PDA) detector (Shimadzu, Japan) and monitored at
298 nm. The total run time was 15 min.
Median dose-corrected vincristine concentration time data for
six animals, three animals at 0.05 mg/kg and three at 0.091 mg/
kg, was combined to investigate the pharmacokinetics of
vincristine in Tasmanian devils. Pharmacokinetic data were
analyzed using non-compartmental methods. The area under
Table 2. Criteria for toxic effects in Tasmanian devils receiving vincristine.
















2 Anorexia ,3 days duration
3 Anorexia .3 days but ,5 days duration





3 1–5 episodes per day, ,2 days
4 6–10 episodes per day, requires hospitalization
Diarrhea
0 None
1 Soft stools, responds to dietary modification
2 1–4 watery stools per day, ,2 days
3 4–7 watery stools per day or .2 days
4 .7 watery stools per day or bloody, requires hospitalization
doi:10.1371/journal.pone.0065133.t002
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the vincristine concentration-time curve until the last time point
(AUC0-t)) was calculated using the linear trapezoidal rule and was
extrapolated to infinity (AUC0-‘)) using the last concentration
observation (Ct) divided by the terminal elimination rate constant
(kel). The terminal elimination rate constant was calculated as the
slope of the terminal portion of the natural log transformed
concentration-time plot. Half-life was estimated as ln 2/kel. The
clearance (CL) was calculated as Dose/(AUC0-‘) and the volume
of distribution (V) was estimated as CL/kel.
Results
Animals and Dosage Rates
Eight Tasmanian devils with early DTFD were entered into this
trial over a period of 27 weeks. The original plan was to only treat
animals at a single dosage level, and to escalate dosages only using
new cohorts of untreated animals. This was not possible due to
limited numbers of animals available for this trial (Table 1). The
interval between treatments at the same dosage level was 1 week.
When dosage levels were changed in an individual, a minimum
break of 3 weeks between treatments was used.
Dosage Escalation Study
The maximally tolerated dosage rate for a single treatment of
vincristine in Tasmanian devils was 0.105 mg/kg. The dose
limiting toxicity was neutropenia, with 3 of 5 animals treated at
that dosage rate showing grade 2 to 4 neutropenia (Table 1). This
would be considered the dosage rate to be used in clinical
evaluation. At the next lowest level (0.091 mg/kg) the maximum
toxicity was Grade 2 neutropenia in 1 of 4 animals. Only one
animal was treated more than once with vincristine at 0.105 mg/
kg, and there was a suggestion of cumulative myelosuppression
(neutropenia grade 0, week 1; grade 2 week 2; and grade 3 week 3)
(Table 1).
Anti-cancer Activity
Anti-cancer activity was not noted at any dosage rate. All
animals treated with vincristine showed either stable disease or
progressive disease. All animals treated in this trial, regardless of
the dosage of chemotherapy they received, were euthanized as the
result of disease progression. There was no decrease in tumor
measurements during the trial; stable disease was maintained for
between 3 weeks and 9 weeks (median 4.5 weeks) in 6 animals, and
PD was noted by 3 weeks in 2 animals (both receiving the MTD or
above). The median survival time for the 8 animals receiving
vincristine was 129 days, which was not significantly different
(p = 0.61) from the median survival time of 83 days for 8 captive
Tasmanian devils with DFTD that did not receive chemotherapy.
Pharmacokinetics
Pharmacokinetic parameters for vincristine in the Tasmanian
Devil are presented in Table 3. Figure 1 shows the median plasma
vincristine concentration-time profiles of vincristine at a dosage
rate of 0.05 mg/kg in the Tasmanian Devil. As expected there was
an initial rapid decline in vincristine plasma concentrations, which
was consistent with the distribution phase.
Discussion
If the DFTD was highly responsive to vincristine, then
chemotherapy might be a tool that could be used to save animals
with important genetic value. In addition, if tumor regression was
associated with the development of immunity to the tumor, it
might provide an important conservation tool. Vincristine was
chosen in this study because, based on clinical experience in cats
[15] and dogs [21], it has relatively few side effects, it is effective as
a single agent against CTVT and was expected to have limited
impact on reproductive capacity of the animals after treatment
[12,22].
Therefore, the initial objective of this study was to determine if a
vincristine dosage rate resulting in an acceptable toxicity level
would be effective against the DFTD. According to Gehan’s
criteria, if no anti-tumor responses are seen in the first 9 animals
treated, then there is a less than 10% probability of the relevant
chemotherapy drug having a true response rate of more than 25%
[23]. We treated 7 animals at a dosage level of 0.105 mg/kg or
above with no response. This makes it unlikely that vincristine
treatment would have a clinically relevant effect on DFTD in a
high proportion of Tasmanian devils. Given that chemotherapeu-
tic drugs that do not have some impact on a tumor when given
individually do not potentiate the impact of other chemotherapies,
it is also unlikely that vincristine would prove beneficial if
combined with other anti-neoplastic drugs.
Neoplastic diseases, in addition to the DFTD, are common in
dasyurids and marsupials in general [16]. Therefore, as there are
no studies on the use of vincristine in a marsupial, it was the
second objective of this study to establish vincristine dosage rates
Figure 1. Median plasma vincristine concentration versus time
for Tasmanian devils (n =6) corrected for a dose of vincristine
0.05 mg/kg.
doi:10.1371/journal.pone.0065133.g001
Table 3. Plasma pharmacokinetic parameters of vincristine in
the Tasmanian devil (median data reported corrected for a
dose of vincristine 0.05 mg/kg).
Parameter/Dose 0.05 mg/kg




Note: AUC(0-‘); area under the concentration time curve extrapolated to infinity
after a dose of vincristine 0.05 mg/kg, CL;clearance, tK; elimination half-life,
V;volume of distribution.
doi:10.1371/journal.pone.0065133.t003
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that can be safely tolerated in the Tasmanian devil so that they
could be used as reference values for vincristine treatments in
other marsupials. Marsupials, including the Tasmanian devil, have
metabolic rates that are significantly lower than those for placental
animals of comparable body mass [24]. It was therefore expected
that vincristine toxicity would be seen at a much lower dosage rate
in the Tasmanian devil as compared to that seen in the cat, dog,
and human. This did not prove to be true, with the treated
Tasmanian devils tolerating a dosage rate (0.105 mg/kg) more
than 4 times the dosage rate given to dogs (0.025 mg/kg) [21], 3
times the dosage rate given to cats (0.0375 mg/kg) [15] and more
than twice the recommended dosage rate for children less than
10 kg in body weight (0.05 mg/kg) [25].
Pharmacokinetic studies were performed to provide insights into
the metabolism and distribution of vincristine in a marsupial and,
although unplanned, provided evidence as to why the Tasmanian
devils were tolerant of high vincristine dosage rates. Pharmaco-
kinetic studies on vincristine are difficult as there is considerable
intra- and inter-subject variability in blood concentrations
following the same dosage rates [26]. Also, most studies contain
many more study subjects than we were able to enter in this study
[26–30]. The assay used in this study to analyze vincristine plasma
concentration in Tasmanian devils was not sensitive enough (limit
of quantification 10 nm/L) to provide late peak concentration for
some individuals. As a result a non-compartment pharmacokinetic
analysis of pooled data for all six treated Tasmanian devils with
DFTD was employed to provide estimates of vincristine pharma-
cokinetic parameters.
Despite the limitations of the pharmacokinetic study, the results
suggest that the pharmacodynamics and not the pharmacokinetics
of vincristine explain the Tasmanian devil’s ability to tolerate
higher than expected dosage rates. The pharmacokinetic param-
eters observed in these studies were similar to those seen in
humans with an expected rapid initial distribution and a long
elimination half-life, consistent with avid and sustained tissue
uptake and binding of vincristine. This is further supported by the
high volume of distribution (1.76 L/kg) suggesting extensive tissue
uptake of vincristine. The elimination half-life in the Tasmanian
devil (approximately 11 h) is similar to adult and infant humans
[19,31,32]. Plasma clearance of vincristine would have been
expected to be more rapid than that observed in humans if rapid
elimination of the drug played a role in their resistance to toxicity.
In contrast, the opposite was observed with the Tasmanian devil
having a relatively slower plasma clearance than humans, as might
be predicted by their lower metabolic rate. The toxicity of
vincristine to tumor cells and presumably to the host cells alike
may, in part, be dependent on the concentration that vincristine
reaches in the cell. It has been shown that over expression of
transmembrane proteins of the ATP-binding cassette (ABC)
protein superfamily are responsible for the resistance of some
tumors to vincristine [33–35]. These enzymes play an important
role in normal cells by removing toxic substances from the
cytoplasm. It is likely that variability in these enzymes to transport
vincristine from cells may occur across species and provides an
explanation for why Tasmanian devils are able to tolerate high
vincristine dosages.
Some degree of toxicity is an inevitable consequence of
chemotherapy, therefore, we documented the toxic effects of
vincristine, the clinical manifestations of these effects, and the
challenges associated with ameliorating the effects when treating a
wild animal. The development of a peripheral neuropathy is the
major limiting toxicity for treatment of humans with vincristine
[25]. In contrast, gastrointestinal toxicity and bone marrow
toxicity limits the dosage rate of vincristine in dogs and cats and
intestinal ileus may occur in cats [15] and less commonly in dogs
[21]. Neurologic defects were not observed in the Tasmanian
devils, however, both bone marrow and apparent gastrointestinal
toxicity were.
Neutropenia was the primary hematological toxicity observed,
and in the one Tasmanian devil, given more than one dose at
0.105 mg/kg, it appeared to be cumulative. Thrombocytopenia
was not seen, and this is consistent with treatment in cats and dogs
where vincristine is considered ‘‘platelet sparing’’ [36]. Anemia
occurred uncommonly in the treated Tasmanian devils and is not
associated with vincristine treatment in other species. Although it
could not be determined with certainty, it is likely that this was the
result of anemia of chronic disease and blood loss from ulcerated
tumors and metastases and was not caused by the vincristine
treatment.
Evaluation of the severity of gastrointestinal toxicities seen in the
animals in these trials was complicated by the feeding habits of
Tasmanian devils and their adjustment to captive living and
feeding. Whether the observed reduction in appetite should be
considered an adverse event of the chemotherapy is uncertain. All
animals were allowed a period to ‘‘acclimatize’’ to captive living,
but that needed to be kept brief (usually 1 to 2 weeks) due to the
rapid progression of tumor growth, and the need to start treatment
before the tumors themselves impacted on their quality of life.
Tumor progression and development of visceral metastases often
causes appetite loss, and other GI signs; this may also complicate
the interpretation of such signs in Tasmanian devils undergoing
treatment.
An unanticipated issue in the trial, unique to this species, was
maintaining appetite while ensuring asepsis to reduce the risk of
infection. Healthy Tasmanian devils in the wild would eat carrion
and thus be exposed to heavy loads of bacteria. While this diet is
clearly tolerated without ill effect in healthy Tasmanian devils,
there was concern that animals debilitated by their disease and
further compromised by the vincristine treatments might become
septic. Providing a varied diet and using a commercial supplement
diet appeared to improve appetite for some animals, but others
would only eat carrion. For these Tasmanian devils, macropods
that had been killed as part of a culling program and immediately
frozen were used as food sources.
The administration of anti-inflammatory drugs, antibiotics and
anti-emetic agents, seemed to improve their general well-being
during the trial. Specifically, the NK-1 antagonist antiemetic
maropitant at the same dosage rate recommended for treatment of
dogs (1 mg/kg once daily, orally) appeared effective in the animals
in the trial.
Conclusion
We found no evidence that the DFTD is susceptible to
vincristine at subtoxic dosage rates. Tasmanian devils, however,
were found to tolerate dosage rates that would have been toxic in
dogs, cats, and humans. This tolerance appears to be the result of
pharmacodynamic and not pharmacokinetic factors. Marsupials
are a diverse groups of animals, and while the data in this paper
forms a basis for the use of vincristine in other marsupial species,
caution should be taken when treating other species as vincristine
metabolism may differ in them.
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